Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
6.66
0.00 (0.00%)
Aug 31, 2026, 4:00 PM EDT - Market closed
Nuvation Bio Revenue
Nuvation Bio had revenue of $31.69M in the quarter ending June 30, 2026, with 555.64% growth. This brings the company's revenue in the last twelve months to $169.90M, up 1,083.56% year-over-year. In the year 2025, Nuvation Bio had annual revenue of $62.90M with 698.96% growth.
Revenue (ttm)
$169.90M
Revenue Growth
+1,083.56%
P/S Ratio
13.76
Revenue / Employee
$557,049
Employees
305
Market Cap
2.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.90M | 55.03M | 698.96% |
| Dec 31, 2024 | 7.87M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
NUVB News
- 10 days ago - Nuvation Bio initiated with an Overweight at Cantor Fitzgerald - TheFly
- 11 days ago - Nuvation Bio granted FDA Fast Track Designation for safusidenib in glioma - TheFly
- 11 days ago - Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma - PRNewsWire
- 14 days ago - Nuvation Bio initiated with an Overweight at JPMorgan - TheFly
- 24 days ago - Nuvation Bio price target raised to $14 from $12 at B. Riley - TheFly
- 24 days ago - Nuvation Bio price target raised to $20 from $19 at RBC Capital - TheFly
- 25 days ago - Nuvation Bio Slides: Corporate presentation - Filings
- 25 days ago - Nuvation Bio Earnings Call Transcript: Q2 2026 - Transcripts